Molecular targeted therapies for breast cancer treatment

Targeting the oestrogen receptor, HER2 (human epidermal growth factor receptor 2) and vascular endothelial growth factor has markedly improved breast cancer therapy. New targeted therapeutic approaches to induction of apoptosis or inhibition of anti-apoptosis, cell cycle progression, signal transduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlotter, Claus M, Vogt, Ulf, Allgayer, Heike, Brandt, Burkhard
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575526/
https://www.ncbi.nlm.nih.gov/pubmed/18671839
http://dx.doi.org/10.1186/bcr2112
_version_ 1782160322413461504
author Schlotter, Claus M
Vogt, Ulf
Allgayer, Heike
Brandt, Burkhard
author_facet Schlotter, Claus M
Vogt, Ulf
Allgayer, Heike
Brandt, Burkhard
author_sort Schlotter, Claus M
collection PubMed
description Targeting the oestrogen receptor, HER2 (human epidermal growth factor receptor 2) and vascular endothelial growth factor has markedly improved breast cancer therapy. New targeted therapeutic approaches to induction of apoptosis or inhibition of anti-apoptosis, cell cycle progression, signal transduction and angiogenesis are described. The molecular pathways and their inhibitory or repair mechanisms are discussed in the preclinical and clinical settings.
format Text
id pubmed-2575526
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-25755262008-10-30 Molecular targeted therapies for breast cancer treatment Schlotter, Claus M Vogt, Ulf Allgayer, Heike Brandt, Burkhard Breast Cancer Res Review Targeting the oestrogen receptor, HER2 (human epidermal growth factor receptor 2) and vascular endothelial growth factor has markedly improved breast cancer therapy. New targeted therapeutic approaches to induction of apoptosis or inhibition of anti-apoptosis, cell cycle progression, signal transduction and angiogenesis are described. The molecular pathways and their inhibitory or repair mechanisms are discussed in the preclinical and clinical settings. BioMed Central 2008 2008-07-24 /pmc/articles/PMC2575526/ /pubmed/18671839 http://dx.doi.org/10.1186/bcr2112 Text en Copyright © 2008 BioMed Central Ltd
spellingShingle Review
Schlotter, Claus M
Vogt, Ulf
Allgayer, Heike
Brandt, Burkhard
Molecular targeted therapies for breast cancer treatment
title Molecular targeted therapies for breast cancer treatment
title_full Molecular targeted therapies for breast cancer treatment
title_fullStr Molecular targeted therapies for breast cancer treatment
title_full_unstemmed Molecular targeted therapies for breast cancer treatment
title_short Molecular targeted therapies for breast cancer treatment
title_sort molecular targeted therapies for breast cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2575526/
https://www.ncbi.nlm.nih.gov/pubmed/18671839
http://dx.doi.org/10.1186/bcr2112
work_keys_str_mv AT schlotterclausm moleculartargetedtherapiesforbreastcancertreatment
AT vogtulf moleculartargetedtherapiesforbreastcancertreatment
AT allgayerheike moleculartargetedtherapiesforbreastcancertreatment
AT brandtburkhard moleculartargetedtherapiesforbreastcancertreatment

Ejemplares similares